Alliance A071701: Genomically guided treatment trial in brain metastases.

TPS2573Background: Brain metastases, most commonly derived from melanoma, lung and breast cancers, are the most common brain tumor, with approximately 200,000 cases diagnosed annually in the United...

[1]  Eudocia Q Lee,et al.  Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study , 2017, Neuro-oncology.

[2]  D. Cahill,et al.  Treatment of brain metastases in the modern genomic era , 2017, Pharmacology & therapeutics.

[3]  T. Betsuyaku,et al.  A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment , 2016, Case reports in oncological medicine.

[4]  N. Yeh,et al.  Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Carter,et al.  Brain Metastasis: Clinical Implications of Branched Evolution. , 2016, Trends in cancer.

[6]  D. Cahill,et al.  Management of brain metastases in the era of targeted and immunomodulatory therapies. , 2015, Oncology.

[7]  W. Curry,et al.  Clinical discussion and review of the management of brain metastases. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  S. Ray,et al.  Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer , 2013, Journal of Neuro-Oncology.

[9]  P. Bunn,et al.  Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  R. Weichselbaum,et al.  Improved survival time trends for glioblastoma using the SEER 17 population-based registries , 2012, Journal of Neuro-Oncology.

[11]  R. Weichselbaum,et al.  Improved survival time trends for glioblastoma using the SEER 17 population-based registries. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Sleeman,et al.  Cancer metastasis as a therapeutic target. , 2010, European journal of cancer.

[13]  D. Kondziolka,et al.  The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline , 2009, Journal of Neuro-Oncology.

[14]  D. Kondziolka,et al.  The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline , 2009, Journal of Neuro-Oncology.

[15]  P. Levendag,et al.  Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. , 1999, International journal of radiation oncology, biology, physics.

[16]  M. Ahluwalia,et al.  Systemic therapy for brain metastases. , 2018, Handbook of clinical neurology.

[17]  Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. , 2015, The New England journal of medicine.

[18]  S. Kalkanis,et al.  Evidence-based guidelines for the management of brain metastases. , 2011, Neurosurgery clinics of North America.